Related News
Henry Ford Health neurosurgery team brings FDA-approved vagus nerve stimulation treatment to Michigan with state’s first commercial implantation
Nurse-led projects on patient safety, workforce well-being and healthcare innovation were recognized at Henry Ford Health’s annual Nursing Research & Evidence-Based Practice Symposium
Henry Ford Health's high-intensity focused ultrasound (HIFU) program expands to treat wider range of Parkinson's symptoms
In The News: Henry Ford Health System and G3 Pharmaceuticals to Develop and Commercialize Treatment for Diastolic Heart Failure
G3 Pharmaceuticals, a development-stage biopharmaceutical company located in Burlington, MA, and Henry Ford Health System, have announced the signing of an exclusive license and option agreement for the development and commercialization of galectin-3 inhibitors for treatment of diastolic heart failure, also known as heart failure with preserved ejection fraction or HFpEF.
Read the full article here: